On Feb. 7, the U.S. Food and Drug Administration announced that drug interactions between the hepatitis C virus protease inhibitor Victrelis (boceprevir) and certain ritonavir-boosted human immunodeficiency virus protease inhibitors (atazanavir, lopinavir, darunavir) can potentially reduce the effectiveness of these medications when they are used in combination. Read more.
Is your Nursing Team an All-Pro Nursing Team? The deadline to enter the 2026 All-Pro Nursing Awards is Monday, March 9th 2026. We want to know how your team has made a difference. Apply now! Also check out last year's winners.
FDA warns of drug interactions between Victrelis and ritonavir-boosted human immunodeficiency virus (HIV) protease inhibitors
Share

















